Tag: Prescription Drugs
ACG: Fewer Overt Hepatic Encephalopathy Episodes Seen With Rifaximin
Rifaximin monotherapy reduces risk for breakthrough OHE episode and results in a lower mortality rate than lactulose monotherapy
ASN: Empagliflozin Offers Lasting Cardiorenal Benefit in CKD Patients
Empagliflozin offers cardiorenal benefits for up to 12 months after discontinuation among CKD patients at risk for progression
ACAAI: Many Anaphylaxis Protocols Are Incomplete, Outdated
Second study shows that only 14 percent of patients correctly identified symptoms requiring epinephrine
ACAAI: Gene-Editing Therapy Reduces Angioedema Attacks in Hereditary Angioedema
Reduction of 75 and 77 percent seen in estimated mean monthly attack rate with 25-mg, 50-mg NTLA-2002 versus placebo
AAO: Corneal Toxicity Reported With Mirvetuximab Soravtansine
Corneal toxicity not uncommon with MIRV treatment for primary gynecologic malignancies, usually resolves
People With Inflammatory Bowel Disease Face Barriers to Health Care
Barriers include access to treatment, insurance barriers, and financial issues
Annual Wasteful Spending on Lecanemab Estimated at $133 to $336 Million
Adding 75-mg vial size would achieve greatest reduction in waste, representing annual savings of $99 million
Retinal Neuroaxonal Loss Detectable With Epilepsy
People with a high number of antiseizure medications seem to be at risk for accelerated neuroaxonal loss
2013 to 2021 Saw Decline in Benzodiazepine Initiation Post-AIS
More than three-quarters of prescriptions were for a supply of more than seven days; 55 percent for 15 to 30 days
Diabetes, High BMI, Previous Metformin Common in Teens With Rx for GLP-1 RAs
Prescriptions for GLP-1 RAs less common among White teens versus Black, Hispanic teens